ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene therapy aims to fix protein deficiency in lung and liver disease
Disease control Recruiting nowThis study tests an experimental gene therapy called TSRA-196 in 72 adults with a severe form of Alpha-1 Antitrypsin Deficiency (the PiZZ genotype) who have lung or liver disease. The treatment is designed to help the body produce more of the protective protein it lacks. The tria…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1, PHASE2 • Sponsor: Tessera Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:12 UTC
-
Hidden gene behind breathlessness? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) is more common in people who have shortness of breath and signs of airway blockage. Researchers will test blood samples from 734 adults to measure AAT protein levels and check for related…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: Muğla Sıtkı Koçman University • Aim: Knowledge-focused
Last updated May 26, 2026 12:02 UTC